SCHEMBL86743

SCHEMBL86743

Nc1nc2ccccc2c2cccn12

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOS2 P35228 1/20 0.48
KDM4E B2RXH2 6/20 0.46
ALDH1A1 P00352 4/20 0.45
SMN1; SMN2 Q16637 4/20 0.45
HPGD P15428 3/20 0.45
GLA P06280 3/20 0.45
CASP1 P29466 2/20 0.45
CASP7 P55210 2/20 0.45
HSD17B10 Q99714 2/20 0.45
TDP1 Q9NUW8 2/20 0.45
CHRM2 P08172 1/20 0.45
ADRA2A P08913 1/20 0.45
ADORA3 P0DMS8 1/20 0.45
CHRM1 P11229 1/20 0.45
NQO2 P16083 1/20 0.45
MAOA P21397 1/20 0.45
DRD1 P21728 1/20 0.45
ACHE P22303 1/20 0.45
SLC6A2 P23975 1/20 0.45
ADRA1A P35348 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31040792 0.75 CSNK2A2 (0.45) KDM4EALDH1A1SMN1; SMN2HPGDHSD17B10
SCHEMBL29013081 0.74 KDM4E (0.54) KDM4EALDH1A1SMN1; SMN2HPGDGLA
SCHEMBL14629325 0.74 KDM4E (0.46) KDM4EALDH1A1SMN1; SMN2HPGDGLA
SCHEMBL87054 0.73 ADORA2A (0.49) KDM4EALDH1A1SMN1; SMN2HPGDGLA
SCHEMBL5983909 0.72 NOS2 (0.45) NOS2KDM4EALDH1A1HPGDGLA
Bromide SCHEMBL80836 0.71 ADORA2A (0.48) KDM4EALDH1A1SMN1; SMN2HPGDGLA
SCHEMBL31377558 0.69 PTPN1 (0.61) NOS2KDM4EALDH1A1HPGDGLA
SCHEMBL31452723 0.69 NOS2 (0.38) NOS2KDM4EALDH1A1SMN1; SMN2HPGD
SCHEMBL31452714 0.69 PTPN1 (0.56) NOS2KDM4EALDH1A1HPGDGLA
SCHEMBL9138426 0.69 HTR3E (0.52) NOS2KDM4EALDH1A1SMN1; SMN2HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2014101373-A1 HETEROBICYCLO-SUBSTITUTED-[1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINE COMPOUNDS FOR TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDER MERCK SHARP & DOHME CORP. (US) 2014-07-03 WO disclosed
US-8129386-B2 Fused azole-pyrimidine derivatives BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2012-03-06 US disclosed
US-20090270388-A1 FUSED AZOLE-PYRIMIDINE DERIVATIVES BAYER PHARMACEUTICALS CORPORATION (US) 2009-10-29 US disclosed
US-7511041-B2 Fused azole-pyrimidine derivatives BAYER PHARMACEUTICALS CORPORATION (US) 2009-03-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090270388-A1 FUSED AZOLE-PYRIMIDINE DERIVATIVES PIK3CA, PIK3CD, PIK3R5 NOS2 826/4885KDM4E 3603/4885ALDH1A1 4300/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.